GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration for its Photonova Spectra photon-counting CT system, marking a key step towards its commercial launch in the United States.
Photonova Spectra introduces photon-counting CT technology, which directly measures individual X-ray photons and their energy, unlike conventional systems that first convert them into visible light.
This enables improved spatial and spectral resolution, helping clinicians detect subtle tissue differences, small lesions, and detailed vascular structures with greater accuracy.
The system is powered by a new Deep Silicon detector, designed to enhance energy measurement and image quality.
It supports advanced material differentiation, allowing clearer distinction between substances such as iodine, calcium, and fat.
With fast rotation speeds and wide detector coverage, it also enables rapid, motion-free imaging.
Photonova Spectra captures ultra-high-definition spatial and spectral data in a single scan without requiring additional setup.
It is supported by NVIDIA-based computing to manage large data volumes efficiently and maintain workflow performance.
The platform is expected to support a wide range of applications, including neurology, oncology, cardiology, and research into advanced imaging techniques and biomarkers.
